BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

22 articles for HC Huang

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Probes for narcotic receptor mediated phenomena. 9. Synthesis of (+/-)-(3 alpha,6a alpha,11a beta)-1,3,4,5,6,11a-hexahydro-2-methyl-2H-3,6a- methanobenzofuro[2,3-c]azocin-10-ol, an oxide-bridged 5-(m-hydroxyphenyl)morphan.EBI
TBA
Discovery of an irreversible HCV NS5B polymerase inhibitor.EBI
Merck Research Laboratories
Anti-inflammatory lanostanoids and lactone derivatives from Antrodia camphorata.EBI
National Sun Yat-Sen University
Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.EBI
Merck Research Laboratories
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.EBI
Pfizer
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.EBI
Pfizer
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2).EBI
Pfizer
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).EBI
Pharmacia
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.EBI
Pfizer
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.EBI
Pfizer
Aminopyridinecarboxamide-based inhibitors: Structure-activity relationship.EBI
Pfizer
 
Selective cyclooxygenase inhibitors: Novel 4-spiro 1,2-diarylcyclopentenes are potent and orally active cox-2 inhibitorsEBI
TBA
 
Diaryl indenes and benzofurans: Novel classes of potent and selective cyclooxygenase-2 inhibitorsEBI
TBA
 
Discovery of nonpeptide potent conformationally restricted angiotensin II receptor antagonistsEBI
TBA
Optimized M24B Aminopeptidase Inhibitors for CARD8 Inflammasome Activation.EBI
Memorial Sloan Kettering Cancer Center
Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.EBI
Pfizer
A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 2,3-disubstituted-4-phenylquinolines.EBI
Searle Discovery
Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships.EBI
Searle Research and Development
Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.EBI
Searle R&D
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.EBI
Searle Research and Development
Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides.EBI
Merck